Pharmaceuticals & Therapeutics

Co-founded by Maria Shriver, MOSH raises $13M to scale its brain health nutrition brand, targeting a national grocery and Target rollout.

Pet Honesty launches "The Honest Difference," a new standard for supplement transparency, and pledges a $1M product donation to pets in need.

RVL Pharmaceuticals claims double-digit growth for its eye drop Upneeq, but as a private firm, its disruptive direct-to-consumer model operates outside public view.

A new global partnership aims to solve key bottlenecks in regenerative medicine by providing standardized, high-quality umbilical cord stem cells to researchers.

Alcami acquires Tjoapack, creating a transatlantic CDMO. The deal, orchestrated by owner Ampersand Capital, signals a major shift in pharma services.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

A new FDA-cleared shoulder implant from FX Shoulder Solutions offers unprecedented flexibility, allowing surgeons to adapt their approach mid-surgery.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

LANGLARA, a new Lantus biosimilar, gains FDA approval, promising more affordable diabetes care. But it faces a tough fight in a competitive market.

A new testing platform from Armatus Bio aims to break a major bottleneck in gene therapy, promising faster paths to cures for rare neuromuscular diseases.

A devastating infant liver disorder meets a potential breakthrough. Satellite Bio's novel cell therapy just received a critical FDA nod, paving the way for trials.

The biopharma firm gets a significant non-dilutive cash infusion, bolstering its finances to advance a promising oncology pipeline without equity dilution.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

Amidst a culture of delayed self-care, CARiNG Pharmacy launches a major campaign to shift women's health from reactive treatment to proactive wellness.